Free Trial

iBio (IBIO) Competitors

iBio logo
$0.73 -0.01 (-0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 -0.01 (-0.70%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IBIO vs. PRLD, GANX, OSTX, RNXT, GRCE, NBRV, KLRS, ELYM, MRSN, and AADI

Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Prelude Therapeutics (PRLD), Gain Therapeutics (GANX), OS Therapies (OSTX), RenovoRx (RNXT), Grace Therapeutics (GRCE), Nabriva Therapeutics (NBRV), Kalaris Therapeutics (KLRS), Eliem Therapeutics (ELYM), Mersana Therapeutics (MRSN), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

iBio vs. Its Competitors

iBio (NYSE:IBIO) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

iBio's return on equity of -73.15% beat Prelude Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -73.15% -45.51%
Prelude Therapeutics N/A -89.18%-69.26%

iBio has higher earnings, but lower revenue than Prelude Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$375K32.29-$24.91MN/AN/A
Prelude Therapeutics$7M7.50-$127.17M-$1.69-0.55

In the previous week, Prelude Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 1 mentions for Prelude Therapeutics and 0 mentions for iBio. Prelude Therapeutics' average media sentiment score of 1.89 beat iBio's score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
iBio Neutral
Prelude Therapeutics Very Positive

7.9% of iBio shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

iBio has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 582.04%. Prelude Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 383.87%. Given iBio's higher probable upside, equities research analysts clearly believe iBio is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Prelude Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Prelude Therapeutics beats iBio on 7 of the 12 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBIO vs. The Competition

MetriciBioPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$12.22M$776.90M$5.70B$21.12B
Dividend YieldN/A4.84%4.69%3.60%
P/E RatioN/A1.4028.0728.44
Price / Sales32.2925.35448.5760.38
Price / CashN/A19.5636.2222.92
Price / Book0.526.798.664.69
Net Income-$24.91M-$4.32M$3.25B$995.51M
7 Day Performance0.29%1.33%4.20%1.64%
1 Month Performance0.42%3.74%10.82%5.92%
1 Year Performance-66.90%8.18%34.70%11.50%

iBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBIO
iBio
1.2553 of 5 stars
$0.73
-0.9%
$5.00
+582.0%
-65.8%$12.22M$375K0.00100
PRLD
Prelude Therapeutics
3.6967 of 5 stars
$0.84
+4.6%
$4.50
+434.4%
-84.4%$47.55M$7M-0.50120Positive News
GANX
Gain Therapeutics
2.3561 of 5 stars
$1.58
-0.3%
$8.20
+419.0%
+55.6%$47.51M$50K-1.8420Gap Up
OSTX
OS Therapies
2.0558 of 5 stars
$1.69
+3.0%
$18.00
+965.1%
N/A$47.49MN/A-1.97N/AGap Up
RNXT
RenovoRx
2.2149 of 5 stars
$1.29
-0.8%
$7.25
+462.0%
+4.8%$47.18M$40K-3.236
GRCE
Grace Therapeutics
2.5508 of 5 stars
$3.39
+0.9%
$12.00
+254.0%
N/A$46.88MN/A-3.81N/APositive News
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
KLRS
Kalaris Therapeutics
0.8669 of 5 stars
$2.42
+1.3%
N/AN/A$45.25MN/A0.00110Analyst Forecast
ELYM
Eliem Therapeutics
N/A$1.51
+3.4%
N/A-82.9%$44.93MN/A-2.859Gap Down
MRSN
Mersana Therapeutics
4.0018 of 5 stars
$0.36
+1.8%
$5.20
+1,347.3%
-84.9%$44.78M$40.50M-0.61150News Coverage
Stock Split
AADI
Aadi Bioscience
0.3745 of 5 stars
$1.80
-2.7%
$1.67
-7.4%
+28.0%$44.46M$25.07M-0.7940

Related Companies and Tools


This page (NYSE:IBIO) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners